Table 1.
Patient characteristics
| FMD (n = 65) | Regular diet (n = 64) | |
|---|---|---|
| Median age (range), years | 49.0 (31–71) | 51.0 (27–71) |
| Median body mass index (range), kg/m2 | 25.7 (19.8–41.2) | 26.0 (19.7–39.0) |
| WHO status | ||
| Grade 0 | 61 (93.8%) | 60 (93.8%) |
| Grade 1 | 3 (4.6%) | 4 (6.3%) |
| Unknown | 1 (1.5%) | 0 (0%) |
| Menopausal status | ||
| Pre/peri | 38 (58.5%) | 31 (48.4%) |
| Post | 27 (41.5%) | 31 (48.4%) |
| Unknown | 0 (0%) | 2 (3.1%) |
| T classification | ||
| T1 | 5 (7.7%) | 6 (9.4%) |
| T2 | 42 (64.6%) | 41 (64.1%) |
| T3 | 17 (26.2%) | 15 (23.4%) |
| T4 | 1 (1.5%) | 2 (3.1%) |
| N classification | ||
| N0 | 29 (44.6%) | 33 (51.6%) |
| N1 | 28 (43.1%) | 26 (40.6%) |
| N2 | 7 (10.8%) | 4 (6.3%) |
| N3 | 1 (1.5%) | 1 (1.6%) |
| Clinical stage | ||
| I (ineligible) | 0 (0%) | 1 (1.6%) |
| II | 51 (78.5%) | 48 (75.0%) |
| III | 14 (21.5%) | 15 (23.4%) |
| HR status | ||
| HR− | 14 (21.5%) | 8 (12.5%) |
| HR+ | 51 (78.5%) | 56 (87.5%) |
| Chemotherapy regimen | ||
| AC-T | 52 (80.0%) | 47 (73.4%) |
| FEC-T | 13 (20.0%) | 17 (26.6%) |
| Grade (BR) | ||
| I | 2 (3.1%) | 2 (3.1%) |
| II | 43 (66.2%) | 42 (65.6%) |
| III | 20 (30.8%) | 19 (29.7%) |
| Unknown | 0 (0%) | 1 (1.6%) |
| Tumortype | ||
| Ductal | 53 (81.5%) | 49 (76.6%) |
| Lobular | 9 (13.8%) | 13 (20.3%) |
| Other | 3 (4.6%) | 2 (3.1%) |
FMD fasting mimicking diet, HR hormone receptor, AC-T doxorubicin/cyclophosphamide followed by docetaxel, FEC-T fluorouracil/epirubicin/cyclophosphamide followed by docetaxel, BR bloom Richardson